Exelixis, Inc. Announces Court Ruling Upholding Key Patents, Delaying Generic

What Happened On August 31, 2026, Exelixis, Inc. (filed on Form 8‑K, Item 8.01) announced that the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25‑1236) affirmed the District of Delaware’s judgment that U.S. Patent Nos. 11,091,439; 11,091,440; and 11,098,015 are not invalid. The Court dismissed as moot MSN Laboratories’ appeal regarding U.S. Patent No. 11,298,349 (which expires February 10, 2032) and vacated the district court’s decision on that point. Based on the opinion, the effective date of any final FDA approval of MSN’s ANDA shall not be earlier than January 15, 2030 — the expiration date of the three affirmed patents — subject to further appeals, regulatory exclusivity, and separate litigation.

Key Details

• Filing: Form 8‑K (Item 8.01) filed August 31, 2026, reporting the Federal Circuit decision in Exelixis, Inc. v. MSN Laboratories (No. 25‑1236).
• Patents affirmed not invalid: U.S. Pat. Nos. 11,091,439; 11,091,440; 11,098,015 (all expiring January 15, 2030).
• MSN appeal dismissed/vacated: Appeal on U.S. Pat. No. 11,298,349 dismissed as moot; that patent expires Feb 10, 2032.
• Related litigation: U.S. Pat. No. 12,128,039 (expires Feb 2032) remains subject to separate litigation with trial currently scheduled for November 2026.
• Regulatory impact: Court held any FDA approval of MSN’s ANDA cannot be earlier than Jan 15, 2030, subject to additional legal/regulatory developments.

Why It Matters For investors, the decision preserves Exelixis’ patent protections tied to the specified patents and could delay the commercial launch of MSN’s proposed generic in the U.S. until at least January 15, 2030 (absent other legal or regulatory changes). That timing can affect potential future competition and revenue expectations for Exelixis’ related product(s). Exelixis also notes these statements are forward‑looking and subject to risks, further appeals, regulatory exclusivity, and outcomes of ongoing litigation.